Expanding spectrum of mast cell activation disorders: Monoclonal and idiopathic mast cell activation syndromes

Clinical Therapeutics

Volumn 35, Issue 5, 2013, Pages 548-562

  Picard, Matthieu ^a   Giavina Bianchi, Pedro ^a   Mezzano, Veronica ^a   Castells, Mariana ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antihistamine; Mast cell activation syndrome; Mastocytosis; Monoclonal; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CALCITONIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MIDOSTAURIN; OMALIZUMAB; QUERCETIN;

ABDOMINAL PAIN; ANAPHYLAXIS; BONE MARROW BIOPSY; CALCITONIN BLOOD LEVEL; CELL ACTIVATION; CHRONIC URTICARIA; CLINICAL FEATURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; FLUID RESUSCITATION; HEADACHE; HUMAN; HYMENOPTERA; IDIOPATHIC MAST CELL ACTIVATION SYNDROME; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; MONOCLONAL MAST CELL ACTIVATION SYNDROME; NONHUMAN; PHEOCHROMOCYTOMA; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; QUALITY OF LIFE; REVIEW; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE;

ANAPHYLAXIS; FEMALE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS; SEX FACTORS; SYNDROME;

EID: 84877923853     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.04.001     Document Type: Review

References (67)

1. Lieberman P., Nicklas R.A., Oppenheimer J., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010, 126:477-480. e1-e42.
2. Valent P., Akin C., Arock M., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
3. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
4. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126:1099-1104. e1094.
5. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
6. Akin C., Scott L.M., Kocabas C.N., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331-2333.
7. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009, 123:680-686.
8. Alvarez-Twose I., Gonzalez de Olano D., Sanchez-Munoz L., et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010, 125:1269-1278. e1262.
9. Alvarez-Twose I., Gonzalez-de-Olano D., Sanchez-Munoz L., et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2012, 157:275-280.
10. Sonneck K., Florian S., Mullauer L., et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007, 142:158-164.
11. Hamilton M.J., Hornick J.L., Akin C., et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011, 128:147-152. e142.
12. Castells M., Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002, 127:147-152.
13. Triggiani M., Patella V., Staiano R.I., et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008, 153(Suppl 1):7-11.
14. Seidel H., Molderings G.J., Oldenburg J., et al. Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost 2011, 106:987-989.
15. Prieto-Garcia A., Zheng D., Adachi R., et al. Mast cell restricted mouse and human tryptase/heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen. J Biol Chem 2012, 287:7834-7844. 9.
16. Nussberger J., Cugno M., Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002, 347:621-622.
17. Cardet J.C., Castells M.C., Hamilton M.J. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep 2013, 13:10-18.
18. Modlin I.M., Kidd M., Latich I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717-1751.
19. Roberts L.J., Marney S.R., Oates J.A. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. N Engl J Med 1979, 300:236-238.
20. Bravo E.L. Pheochromocytoma: new concepts and future trends. Kidney Int 1991, 40:544-556.
21. Perry C.G., Sawka A.M., Singh R., et al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007, 66:703-708.
22. Strosberg J.R. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol 2013, 40:120-133.
23. Thieben M.J., Sandroni P., Sletten D.M., et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007, 82:308-313.
24. Shibao C., Arzubiaga C., Roberts L.J., et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005, 45:385-390.
25. Schwartz L.B., Bradford T.R., Rouse C., et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994, 14:190-204.
26. Hogan A.D., Schwartz L.B. Markers of mast cell degranulation. Methods 1997, 13:43-52.
27. Awad J.A., Morrow J.D., Roberts L.J. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994, 93:817-824.
28. Butterfield J.H., Weiler C.R. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008, 147:338-343.
29. Commins S.P., Platts-Mills T.A. Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). Curr Allergy Asthma Rep 2013, 13:72-77.
30. Wang S.A., Hutchinson L., Tang G., et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components. Am J Hematol 2013, 88:219-224.
31. Horny H.P., Sotlar K., Valent P. Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol 2012, 159:1-5.
32. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010, 125:719-726. 726 e711-726 e714.
33. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
34. Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12:259-270.
35. Pardanani A. Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol Oncol Clin North Am 2012, 26:1117-1128.
36. Gonzalez-de-Olano D., Alvarez-Twose I., Vega A., et al. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011, 3:637-651.
37. Bonadonna P., Zanotti R., Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
38. Gonzalez de Olano D., Alvarez-Twose I., Esteban-Lopez M.I., et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008, 121:519-526.
39. Bonadonna P., Zanotti R., Caruso B., et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008, 121:256-257.
40. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008, 63:376-378.
41. Brockow K., Bonadonna P. Drug allergy in mast cell disease. Curr Opin Allergy Clin Immunol 2012, 12:354-360.
42. Turk J., Oates J.A., Roberts L.J. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983, 71:189-192.
43. Akin C. Anaphylaxis and mast cell disease: what is the risk?. Curr Allergy Asthma Rep 2010, 10:34-38.
44. Simons F.E. Advances in H1-antihistamines. N Engl J Med 2004, 351:2203-2217. 18.
45. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14:659-687. vii.
46. Kettelhut B.V., Berkebile C., Bradley D., Metcalfe D.D. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol 1989, 83:866-870.
47. Czarnetzki B.M. A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa. Dermatologica 1983, 166:44-47.
48. Povoa P., Ducla-Soares J., Fernandes A., Palma-Carlos A.G. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991, 229:475-477.
49. Gasior-Chrzan B., Falk E.S. Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists. Dermatology 1992, 184:149-152.
50. Frieri M., Alling D.W., Metcalfe D.D. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 1985, 78:9-14.
51. Johnson G.J., Silvis S.E., Roitman B., et al. Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists. Am J Gastroenterol 1980, 74:485-489.
52. Hirschowitz B.I., Groarke J.F. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med 1979, 90:769-771.
53. Soter N.A., Austen K.F., Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979, 301:465-469.
54. Horan R.F., Sheffer A.L., Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990, 85:852-855.
55. Okayama Y., Benyon R.C., Rees P.H., et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992, 22:401-409.
56. Weng Z., Zhang B., Asadi S., et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 2012, 7:e33805.
57. Vieira Dos Santos R., Magerl M., Martus P., et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010, 162:674-676.
58. Tolar J., Tope W.D., Neglia J.P. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004, 350:735-736.
59. Turner P.J., Kemp A.S., Rogers M., Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012, 29:222-223.
60. Sancho-Chust J.N., Chiner E., Camarasa A., Llombart M. Recent-onset bronchial asthma as a manifestation of systemic mastocytosis. J Investig Allergol Clin Immunol 2009, 19:513-515.
61. Butterfield J.H., Kao P.C., Klee G.C., Yocum M.W. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 1995, 70:481-487.
62. Lorcerie B., Arveux I., Chauffert B., et al. Aspirin and systemic mastocytosis. Lancet 1989, 2(8672):1155. 11.
63. Bell M.C., Jackson D.J. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012, 108:383-384.
64. Molderings G.J., Raithel M., Kratz F., et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med 2011, 50:611-615.
65. Chang T.W., Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006, 117:1203-1212. quiz 1213.
66. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 2013, 90:89-98.
67. Kempuraj D., Castellani M.L., Petrarca C., et al. Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. Clin Exp Med 2006, 6:150-156.